Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Qiagen ( (QGEN) ) has shared an announcement.
Qiagen disclosed that the Dutch financial markets regulator AFM has notified the company of a substantial shareholding position held by Goldman Sachs Group Inc. in Qiagen. The filing shows Goldman Sachs holds a combined 2.87% capital and voting interest in Qiagen through a mix of ordinary shares, swaps, call options, convertible bonds and warrants, largely on an indirect and mostly potential basis.
The position is distributed across several Goldman Sachs entities, including Goldman Sachs International, Goldman Sachs Bank USA, Goldman Sachs & Co. LLC and Goldman Sachs Bank Europe SE, with only a small portion classified as real rather than potential holdings. While Qiagen stresses it is not responsible for the accuracy of the AFM disclosure, the notification underscores ongoing institutional investor interest in the stock and provides transparency on derivatives-based exposure to the company’s equity.
The most recent analyst rating on (QGEN) stock is a Buy with a $58.00 price target. To see the full list of analyst forecasts on Qiagen stock, see the QGEN Stock Forecast page.
More about Qiagen
Qiagen N.V. is a Netherlands-based life sciences company specializing in sample and assay technologies used in molecular diagnostics, applied testing, academic research and pharmaceutical development. Its shares are listed on several European exchanges as well as the NYSE and Swiss markets, reflecting its role as an internationally traded provider of laboratory and diagnostics solutions.
Average Trading Volume: 2,103,103
Technical Sentiment Signal: Strong Buy
Current Market Cap: $10.03B
For detailed information about QGEN stock, go to TipRanks’ Stock Analysis page.